A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

Clinical Pharmacology and Therapeutics

Volumn 76, Issue 5, 2004, Pages 490-502

  Innocenti, Federico ^a   Undevia, Samir D ^a   Ramírez, Jacqueline ^a   Mani, Sridhar ^a   Schilsky, Richard L ^a   Vogelzang, Nicholas J ^a   Prado, Marisol ^a   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Chicago IL 60637 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYCLOSPORIN A; DIPHENHYDRAMINE; DIPHENOXYLATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; OPIATE; PHENOBARBITAL; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADULT; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG FEVER; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INSOMNIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; PHENOBARBITAL;

EID: 7944223784     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.07.016     Document Type: Article

References (36)

1. S. Negoro, M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki, K. Matsui Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer J Natl Cancer Inst 83 1991 1164 1168
2. M.L. Rothenberg, J.G. Kuhn, H.A. Burris III, J. Nelson, J.R. Eckardt, M. Tristan-Morales Phase I and pharmacokinetic trial of weekly CPT-11 J Clin Oncol 11 1993 2194 2204
3. C.S. Fuchs, M.R. Moore, G. Harker, L. Villa, D. Rinaldi, J.R. Hecht Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer J Clin Oncol 21 2003 807 814
4. A. Santos, S. Zanetta, T. Cresteil, A. Deroussent, F. Pein, E. Raymond Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin Cancer Res 6 2000 2012 2020
5. L. Iyer, C.D. King, P.F. Whitington, M.D. Green, S.K. Roy, T.R. Tephly Genetic predisposition to the metabolism of irinotecan (CPT-11) Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 101 1998 847 854
6. E. Gupta, T.M. Lestingi, R. Mick, J. Ramirez, E.E. Vokes, M.J. Ratain Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 54 1994 3723 3725
7. E. Gupta, R. Mick, J. Ramirez, X. Wang, T.M. Lestingi, E.E. Vokes Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J Clin Oncol 15 1997 1502 1510
8. E. Gupta, A.R. Safa, X. Wang, M.J. Ratain Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A Cancer Res 56 1996 1309 1314
9. E. Gupta, X. Wang, J. Ramirez, M.J. Ratain Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital Cancer Chemother Pharmacol 39 1997 440 444
10. B.I. Sikic, G.A. Fisher, B.L. Lum, N.A. Brophy, A.M. Yahanda, K.M. Adler Clinical reversal of multidrug resistance Cancer Treat Res 73 1994 149 165
11. N.L. Bartlett, B.L. Lum, G.A. Fisher, N.A. Brophy, M.N. Ehsan, J. Halsey Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance J Clin Oncol 12 1994 835 842
12. A.M. Yahanda, K.M. Alder, G.A. Fisher, N.A. Brophy, J. Halsey, R.I. Hardy Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance J Clin Oncol 10 1992 1624 1634
13. X.Y. Chu, Y. Kato, K. Niinuma, K.I. Sudo, H. Hakusui, Y. Sugiyama Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats J Pharmacol Exp Ther 281 1997 304 314
14. B.L. Lum, G.A. Fisher, N.A. Brophy, A.M. Yahanda, K.M. Adler, S. Kaubisch Clinical trials of modulation of multidrug resistance Pharmacokinetic and pharmacodynamic considerations Cancer 72 Suppl 1993 3502 3514
15. Cancer Therapy Evaluation Program of the National Cancer Institute. Available from: URL: http://ctep.cancer.gov. Accessed Feb 20, 2004.
16. M. de Forni, R. Bugat, G.G. Chabot, S. Culine, J.M. Extra, A. Gouyette Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients Cancer Res 54 1994 4347 4354
17. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, G. Stoter Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 7 2001 2182 2194
18. J.D. Chester, S.P. Joel, S.L. Cheeseman, G.D. Hall, M.S. Braun, J. Perry Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer J Clin Oncol 21 2003 1125 1132
19. B.M. Foxwell, A. Mackie, V. Ling, B. Ryffel Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein Mol Pharmacol 36 1989 543 546
20. S. Kinoshita, H. Suzuki, K. Ito, K. Kume, T. Shimizu, Y. Sugiyama Transfected rat cMOAT is functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells Pharm Res 15 1998 1851 1856
21. K. Arimori, N. Kuroki, M. Hidaka, T. Iwakiri, K. Yamsaki, M. Okumura Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats Pharm Res 20 2003 910 917
22. J.G. Slatter, L.J. Schaaf, J.P. Sams, K.L. Feenstra, M.G. Johnson, P.A. Bombardt Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos 28 2000 423 433
23. D. Schrenk, P.R. Baus, N. Ermel, C. Klein, B. Vorderstemann, H.M. Kauffmann Up-regulation of transporters of the MRP family by drugs and toxins Toxicol Lett 120 2001 51 57
24. D.R. Johnson, C.D. Klaassen Regulation of rat multidrug resistance protein 2 by classes of prototypical microsomal enzyme inducers that activate distinct transcription pathways Toxicol Sci 67 2002 182 189
25. E.G. Schuetz, W.T. Beck, J.D. Schuetz Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells Mol Pharmacol 49 1996 311 318
26. J.K. Ritter, F.K. Kessler, M.T. Thompson, A.D. Grove, D.J. Auyeung, R.A. Fisher Expression and inducibility of the human bilirubin UDP- glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences Hepatology 30 1999 476 484
27. K.R. Crews, C.F. Stewart, D. Jones-Wallace, S.J. Thompson, P.J. Houghton, R.L. Heideman Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy Clin Cancer Res 8 2002 2202 2209
28. H.S. Friedman, W.P. Petros, A.H. Friedman, L.J. Schaaf, T. Kerby, J. Lawyer Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 1999 1516 1525
29. M.R. Gilbert, J.G. Supko, T. Batchelor, G. Lesser, J.D. Fisher, S. Piantadosi Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma Clin Cancer Res 9 2003 2940 2949
30. U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, Y.M. Rustum Irinotecan in the treatment of colorectal cancer: clinical overview Clin Oncol 19 2001 1501 1518
31. M.J. Ratain Irinotecan dosing: does the CPT in CPT-11 stand for Can't Predict Toxicity? J Clin Oncol 20 2002 7 8
32. X.Y. Chu, H. Suzuki, K. Ueda, Y. Kato, S. Akiyama, Y. Sugiyama Active efflux of CPT-11 and its metabolites in human KB-derived cell lines J Pharmacol Exp Ther 288 1999 735 741
33. M. Maliepaard, M.A. van Gastelen, A. Tohgo, F.H. Hausheer, R.C. van Waardenburg, L.A. de Jong Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918 Clin Cancer Res 7 2001 935 941
34. W.J. Jansen, T.M. Hulscher, J. van Ark-Otte, G. Giaccone, H.M. Pinedo, E. Boven CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein Br J Cancer 77 1998 359 365
35. T. Walle, Y. Otake, A. Galijatovic, J.K. Ritter, U.K. Walle Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2 Drug Metab Dispos 28 2000 1077 1082
36. A. Galijatovic, Y. Otake, U.K. Walle, T. Walle Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation Pharm Res 18 2001 374 379